Author

J. C. Costello

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 5 Physiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 6 Organism:human· 5 Assay:bulk RNA-seq· 3 Research Focus:cell type annotation· 3 Assay:proteomics· 3 Research Focus:differential expression· 2 Research Focus:drug response / drug discovery· 2 Research Focus:gene regulatory network inference· 2

Frequent Co-Authors

A. E. Goodspeed· 2 shared M. J. Sikora· 2 shared M. Joshi· 2 shared A. Clauset· 1 shared A. D. Durbin· 1 shared A. D'Alessandro· 1 shared A. Goodspeed· 1 shared A. J. Lazar· 1 shared

Activity by Year

2019-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 9 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. E. Goodspeed

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

Microparticle-delivered Cxcl9 prolongs Braf inhibitor efficacy in melanoma

G. Romano, F. Paradiso, P. Li, P. Shukla, L. N. Barger, O. El Naggar, J. P. Miller, R. J. Liang, T. L. Helms, A. J. Lazar, J. A. Wargo, F. Taraballi, J. C. Costello, L. N. Kwong

The paper shows that delivering Cxcl9 via microparticles enhances the effectiveness of BRAF inhibitors in melanoma by reducing minimal residual disease relapse.

bioRxiv · May 24, 2022Cancer Biology

SIX1 Reprograms Myogenic Transcription Factors to Maintain the Rhabdomyosarcoma undifferentiated state

J. Y. Hsu, E. P. Danis, S. Nance, J. O'Brien, V. M. Wessells, A. E. Goodspeed, J. C. Talbot, S. L. Amacher, P. Jedlicka, J. C. Black, J. C. Costello, A. D. Durbin, K. B. Artinger, H. L. Ford

This study shows that SIX1 maintains the undifferentiated state of rhabdomyosarcoma cells by altering MYOD1 activity and enhancer regulation, and a SIX1 loss gene signature predicts RMS progression.

bioRxiv · Apr 25, 2021Cancer Biology

NPEPPS is a novel and druggable driver of platinum resistance

R. T. Jones, M. Scholtes, A. Goodspeed, M. M. Akbarzadeh, S. Mohapatra, L. E. Feldman, H. Vekony, A. Jean, C. B. Tilton, M. V. Orman, S. Romal, C. Deiter, T. W. Kan, N. Xander, S. Araki, , J. C. Costello

This study identifies NPEPPS as a driver of cisplatin resistance in bladder cancer and shows its inhibition can enhance cisplatin efficacy in preclinical models.

bioRxiv · Mar 4, 2021 · PreprintCancer Biology

Mediator of DNA damage checkpoint 1 (MDC1) is a novel estrogen receptor co-regulator in invasive lobular carcinoma of the breast

E. K. Bordeaux, J. L. Sottnik, S. Mehrotra, S. E. Ferrara, A. E. Goodspeed, J. C. Costello, M. J. Sikora

This study identifies MDC1 as a novel ER co-regulator in ILC that promotes ER-driven proliferation and anti-estrogen resistance.

bioRxiv · Dec 16, 2020Cancer Biology

The capacity of the ovarian cancer tumor microenvironment to integrate inflammation signaling conveys a shorter disease-free interval

K. R. Jordan, M. J. Sikora, J. E. Slansky, A. Minic, J. K. Richer, M. R. Moroney, J. C. Costello, A. Clauset, K. Behbakht, T. R. Kumar, B. G. Bitler

This study identifies an IL-6/IER3 inflammatory signaling axis linked to chemo-resistance in ovarian cancer by analyzing pre- and post-chemotherapy tumor microenvironment changes.

Clinical Cancer Research · Dec 1, 2020Peer-reviewedCancer Biology

Trisomy 21 activates the kynurenine pathway via increased dosage of interferon receptors

R. K. Powers, K. D. Sullivan, R. Culp-Hill, M. P. Ludwig, K. P. Smith, K. A. Waugh, R. Minter, K. D. Tuttle, H. C. Lewis, A. L. Rachubinski, R. E. Granrath, R. B. Wilkerson, D. E. Kahn, M. Joshi, A. D'Alessandro, , J. M. Espinosa

This study identifies a mechanism by which Trisomy 21 increases kynurenine pathway activity through overexpression of interferon receptors, leading to immunosuppression and neurotoxicity in Down syndrome.

bioRxiv · Jan 11, 2019Physiology